Filippi Luca, Valentini Fabrizio Benedetti, Gossetti Bruno, Gossetti Francesco, De Vincentis Giuseppe, Scopinaro Francesco, Massa Rita
Nuclear Medicine Section, Department of Radiological Sciences, University of Rome "La Sapienza", Rome, Italy.
Tumori. 2005 Mar-Apr;91(2):173-6. doi: 10.1177/030089160509100213.
The aim of this study was to assess whether intraoperative radiolocalization of head and neck paragangliomas with 111In-pentetreotide may increase surgical effectiveness, reducing the risk of recurrence.
Our study included eight patients with untreated, recently diagnosed paragangliomas (four unilateral and four bilateral tumors of the carotid body). After i.v. injection of approximation 150 MBq 111In-pentetreotide, preoperative somatostatin receptor scintigraphy (SRS) was performed. SPECT of the neck was performed at four hours and planar images of the head and neck were also obtained at four and 24 hours post injection. Scintigraphy was always compared with the results of conventional imaging methods (MRI, angiography and sonography). Intraoperative detection was performed on 11 lesions 24 hours after radiopharmaceutical administration using a handheld gamma probe.
Preoperative SRS showed high radiotracer uptake in all patients. All the intraoperatively detected lesions were radically resected and histologically confirmed to be involved by tumor. No false positive results were recorded. Gamma probe detection revealed a small intracranial extension not detected by other imaging methods in a patient with a paraganglioma of the right carotid, and partial involvement of the carotid artery in another patient. During follow-up (median 3.5 years; range, 4 months-7 years) all patients remained disease free according to all parameters.
To our knowledge, this is the first experience of radioguided surgery in paraganglioma. Although our study included a relatively small number of patients, we suggest that intraoperative gamma probe detection may be a powerful tool to improve surgical effectiveness.
本研究旨在评估使用¹¹¹铟-喷替肽对头颈部副神经节瘤进行术中放射性定位是否可提高手术效果,降低复发风险。
我们的研究纳入了8例未经治疗、近期诊断为副神经节瘤的患者(4例单侧和4例双侧颈动脉体肿瘤)。静脉注射约150MBq¹¹¹铟-喷替肽后,进行术前生长抑素受体闪烁显像(SRS)。在4小时时进行颈部单光子发射计算机断层显像(SPECT),并在注射后4小时和24小时获取头颈部的平面图像。闪烁显像结果始终与传统成像方法(磁共振成像、血管造影和超声检查)的结果进行比较。在给予放射性药物24小时后,使用手持式γ探测器对11个病灶进行术中检测。
术前SRS显示所有患者均有高放射性示踪剂摄取。所有术中检测到的病灶均被根治性切除,组织学证实为肿瘤累及。未记录到假阳性结果。γ探测器检测发现1例右侧颈动脉副神经节瘤患者存在其他成像方法未检测到的小的颅内扩展,另1例患者颈动脉部分受累。在随访期间(中位时间3.5年;范围4个月至7年),根据所有参数,所有患者均无疾病复发。
据我们所知,这是副神经节瘤放射性引导手术的首次经验。尽管我们的研究纳入的患者数量相对较少,但我们认为术中γ探测器检测可能是提高手术效果的有力工具。